New Biomarkers Identified for Early Detection of Alzheimer Disease
Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.
Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-ILD Trial in Progressive Pulmonary Fibrosis
Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.
Heart Disease Remains Leading Cause of Death in US: Daily Dose
Your daily dose of the clinical news you may have missed.
Suzetrigine (Journvax) Fits Neatly in a Multimodal Strategy to Manage Acute Pain, According to Edward Mariano, MD, MAS
Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.
Headaches and Suicide
The risk of a suicide attempt was 2 times greater among those with headache, across types including tension type headache, migraine, trigeminal autonomic cephalalgia, and posttraumatic headache.
FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis
Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.
FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C
The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.
Elevated Suicide Risk Identified in People with Headache Disorders
Post-traumatic headaches and trigeminal autonomic cephalalgia significantly increased the risk for attempted and completed suicide, according to new study.
Use of Perioperative Multimodal Pain Management in the US Remains Low, Expert Says
An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.
Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain
AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.
FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose
FDA Approves AbbVie's Combination Antibiotic Emblaveo for Complicated Intra-Abdominal Infections
The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.
Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate
The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.
Nasal COVID-19 Vaccine Poised to Enter Phase 1 US Clinical Trial
The study will assess the safety and efficacy of a next-generation COVID-19 vaccine via nasal spray and inhalation.
FDA Grants Priority Review to Brensocatib, First Targeted Treatment for Bronchiectasis
The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.
US Dementia Cases to Double by 2060: Daily Dose
Hims & Hers Super Bowl Ad for Semaglutide "Nothing Short of Reckless," Says Partnership for Safe Medicines
In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.
FDA Approves New Wearable Treatment for Parkinson Disease
Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.
Opioid Prescribing Has Come a Long Way, According to Stanford Pain Expert Edward Mariano, MD, MAS
Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.
Diabetes Caution: FDA Warns of Risk of Missing Critical Alerts from Smartphone-Compatible Diabetes Devices
Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.
